Skip to main content

Silk Road Medical Names Rick Anderson to Board of Directors

Written by Customer Service on . Posted in Public Companies.

SUNNYVALE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that medical device industry veteran Rick Anderson has joined its board of directors.
Anderson brings over 30 years of senior executive leadership experience in the medical device industry. He is the Chairman and Managing Director of Revival Healthcare Capital, a sustainable, high impact investment firm that specializes in medical devices and diagnostics. He currently serves on the boards of Apollo Endosurgery (Nasdaq: APEN) and Cardiologs, a leading cardiovascular artificial intelligence company; on the Executive Advisory Board of LEK Consulting, a leading healthcare consulting firm; and as an Independent Director of ConvaTec Group Plc, a FTSE 250 company specializing in medical products and related technologies. Anderson previously served as Chairman of the Board and CEO of ConvaTec Group Plc, where in his one-year interim roles he created additional shareholder value through his “Pivot to Growth” strategy and new $150 million transformation plan. He also previously served as Chairman of the Board for Cardiva Medical, IDEV Technologies, and Tryton Medical, and served as Director on the boards of Intersect ENT and multiple other medical device companies.Prior to founding Revival, Anderson served as a Managing Director at PTV Healthcare Capital, a venture capital and private equity firm specializing in the healthcare and life science industries. He also served as the Company Group Chairman of Johnson & Johnson and Worldwide Franchise Chairman of Cordis Corporation. Anderson was a key architect behind the launch of the world’s first drug-eluting stent, the CYPHER® Sirolimus-eluting Coronary Stent. Anderson holds a B.B.A. in Marketing from Mississippi State University.“Rick is an acclaimed leader in the medical device industry with notable experience as a board member working to drive growth,” said Erica Rogers, Chief Executive Officer. “I look forward to his insight and guidance as we continue to advance TCAR’s role in preventing stroke.”“Silk Road Medical has revolutionized the treatment of carotid artery disease and I am honored to be joining the Board of Directors,” said Anderson. “I am excited to be working with this wonderful team to continue to expand their tremendous market opportunities.”About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.About Revival Healthcare Capital
Revival Healthcare Capital is a sustainable, high impact investment platform specializing in the medical device and diagnostic sectors of healthcare. To learn more, visit rvlhc.com.Investors:
Lynn Lewis or Caroline Paul
Gilmartin Group
investors@silkroadmed.comMedia:
Michael Fanucchi
Silk Road Medical
mfanucchi@silkroadmed.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.